What You Must Know About Silence Therapeutics plc’s (LON:SLN) Financial Strength

Zero-debt allows substantial financial flexibility, especially for small-cap companies like Silence Therapeutics plc (LON:SLN), as the company does not have to adhere to strict debt covenants. However, it also faces higher cost of capital given interest cost is generally lower than equity. While SLN has no debt on its balance sheet, it doesn’t necessarily mean it exhibits financial strength. I will take you through a few basic checks to assess the financial health of companies with no debt.

See our latest analysis for Silence Therapeutics

Does SLN’s growth rate justify its decision for financial flexibility over lower cost of capital?

Debt capital generally has lower cost of capital compared to equity funding. But the downside of having debt in a company’s balance sheet is the debtholder’s higher claim on its assets in the case of liquidation, as well as stricter capital management requirements. Either SLN does not have access to cheap capital, or it may believe this trade-off is not worth it. This makes sense only if the company has a competitive edge and is growing fast off its equity capital. Opposite to the high growth we were expecting, SLN’s negative revenue growth of -100% hardly justifies opting for zero-debt. If the decline sustains, it may find it hard to raise debt at an acceptable cost.

AIM:SLN Historical Debt December 21st 18
AIM:SLN Historical Debt December 21st 18

Can SLN meet its short-term obligations with the cash in hand?

Since Silence Therapeutics doesn’t have any debt on its balance sheet, it doesn’t have any solvency issues, which is a term used to describe the company’s ability to meet its long-term obligations. However, another measure of financial health is its short-term obligations, which is known as liquidity. These include payments to suppliers, employees and other stakeholders. With current liabilities at UK£3.6m, it seems that the business has been able to meet these obligations given the level of current assets of UK£38m, with a current ratio of 10.64x. Having said that, a ratio greater than 3x may be considered high by some.

Next Steps:

Given that Silence Therapeutics is a relatively low-growth company, not taking advantage of lower cost debt may not be the best strategy. As an investor, you may want to figure out if there are company-specific reasons for not having any debt, and why financial flexibility is needed at this stage in its business cycle. Keep in mind I haven’t considered other factors such as how SLN has been performing in the past. I suggest you continue to research Silence Therapeutics to get a better picture of the stock by looking at:

  1. Historical Performance: What has SLN’s returns been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
  2. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

To help readers see past the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price-sensitive company announcements.

The author is an independent contributor and at the time of publication had no position in the stocks mentioned. For errors that warrant correction please contact the editor at editorial-team@simplywallst.com.